Daily NSE closing prices — this stock isn't in the live-tracked universe yet.
NSE Close — 25 Sep 2026
₹704.7
Change
+17.65 (2.57%)
Open
₹685.1
Prev. Close
₹687.05
Day High
₹715.0
Day Low
₹670.0
Volume Analysis
Traded
433,524
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (21.5%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹768.14 | ₹741.57 | ₹723.14 | ₹696.57 | ₹678.14 | ₹651.57 | ₹633.14 |
| Fibonacci | ₹741.57 | ₹724.38 | ₹713.76 | ₹696.57 | ₹679.38 | ₹668.76 | ₹651.57 |
| Camarilla | ₹717.08 | ₹712.95 | ₹708.83 | ₹696.57 | ₹700.58 | ₹696.45 | ₹692.33 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+334.7%
1 Week
+6.52%
1 Month
+19.83%
3 Months
+30.6%
6 Months
+207.19%
1 Year
+386.7%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹176.19
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.95%
Net margin 14.13% × asset turnover 0.62x × equity multiplier 1.25x
Company Overview
Sector
Healthcare
Market Cap
₹7,486 Cr
P/E (TTM)
54.4
ROE
11.8%
Book Value
₹113.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.
TopFund Analysis
Bliss Gvs Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Valuation (12/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
64/100 — AverageData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- −Stock is trading at 6.25 times its book value
- −The company has delivered a poor sales growth of 9.94% over past five years.
- −Company has a low return on equity of 10.2% over last 3 years.
- −Company has high debtors of 204 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Shareholders approved appointment of Santosh Parab as Non-Executive, Non-Independent Director; 97.04% votes in favour.
The ESOP Allotment Committee of the Company at its meeting held on today i.e. September 04, 2026 has approved the allotment of 55,250 equity shares …
Post-offer advertisement for Anupam Rasayan’s 26% open offer in Bliss GVS Pharma; 1,669 shares acquired.
The Newspaper Publication regarding the extension of the Special Window for Re-Lodgement of Transfer Request of Physical Shares.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Expenses + | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 |
| Operating Profit | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 |
| OPM % | 15.0% | 26.0% | 22.0% | 14.0% | 19.0% | 19.0% | 14.0% | 11.0% | 20.0% | 18.0% | 16.0% | 17.0% | 27.0% |
| Other Income + | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 |
| Interest | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 |
| Profit before tax | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Tax % | 34.0% | 27.0% | 27.0% | 24.0% | 26.0% | 28.0% | 29.0% | 29.0% | 30.0% | 30.0% | 39.0% | 18.0% | 32.0% |
| Net Profit + | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS in Rs | 1 | 4 | 3 | -1 | 2 | 2 | 2 | 1 | 4 | 3 | 2 | 3 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 927 | 1,005 |
| Expenses + | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 760 | 806 |
| Operating Profit | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 168 | 199 |
| OPM % | 25.0% | 29.0% | 25.0% | 24.0% | 18.0% | 18.0% | 18.0% | 16.0% | 16.0% | 20.0% | 16.0% | 18.0% | 20.0% |
| Other Income + | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | 0 | 36 | 67 | 45 |
| Interest | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 12 | 7 |
| Depreciation | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 33 | 35 |
| Profit before tax | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 190 | 202 |
| Tax % | 36.0% | 32.0% | 36.0% | 39.0% | 30.0% | 26.0% | 29.0% | 57.0% | 28.0% | 30.0% | 28.0% | 29.0% | — |
| Net Profit + | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 | 142 |
| EPS in Rs | 6 | 8 | 8 | 6 | 12 | 9 | 7 | 1 | 7 | 7 | 8 | 12 | 13 |
| Dividend Payout % | 12.0% | 6.0% | 8.0% | 18.0% | 8.0% | 5.0% | 8.0% | 34.0% | 7.0% | 7.0% | 6.0% | 4.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1,040 | 1,182 |
| Borrowings + | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | 22 |
| Other Liabilities + | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 163 | 278 |
| Total Liabilities | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,492 |
| Fixed Assets + | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | 459 |
| CWIP | 0 | 9 | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 | 5 |
| Other Assets + | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 871 | 1,022 |
| Total Assets | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,157 | 1,212 | 1,301 | 1,492 |
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 | 139 |
| Cash from Investing Activity + | -29 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -83 | -75 | -38 |
| Cash from Financing Activity + | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | -89 |
| Net Cash Flow | -34 | 23 | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 | 0 | 11 |
| CFO/OP | 45 | 101 | 160 | 29 | -8 | 69 | 87 | 143 | 67 | 91 | 112 | 108 |
| Free Cash Flow | 5 | 101 | 186 | -7 | 2 | -12 | 55 | 63 | -59 | 75 | 33 | 84 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 42.0% | 43.08% | 43.71% | 45.27% | 46.49% | 44.84% | 44.98% | 45.37% | 45.36% | 44.32% | 49.15% | 47.45% |
| Promoters | 35.06% | 34.97% | 34.97% | 34.9% | 34.82% | 35.1% | 35.29% | 35.44% | 35.39% | 35.36% | 35.36% | 35.01% |
| FII | 16.31% | 15.35% | 14.74% | 13.24% | 12.13% | 13.51% | 13.18% | 12.65% | 13.27% | 14.54% | 10.45% | 8.07% |
| DII | 6.61% | 6.6% | 6.59% | 6.58% | 6.56% | 6.55% | 6.55% | 6.54% | 5.98% | 5.78% | 5.04% | 9.46% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Bliss Gvs Pharma Ltd (this stock) | 7,486 | 54.4 | 6.23 | 11.8% |
| Innova Captab Limited | 7,402 | 48.1 | 6.78 | 13.7% |
| Sanofi India Limited | 7,232 | 16.4 | 8.4 | 47.1% |
| Nephrocare Health Serv L | 7,005 | 82.3 | 6.28 | 8.83% |
| Sun Pharma Adv.res.co.ltd | 6,784 | 4.25 | 5.06 | 279.0% |
| Kovai Medical Center & Ho | 6,653 | 115.0 | 23.07 | 22.2% |
| Morepen Lab. Ltd | 6,596 | 56.2 | 5.26 | 5.33% |
Which Mutual Funds Hold Bliss Gvs Pharma Ltd?
Frequently Asked Questions about Bliss Gvs Pharma Ltd
Bliss Gvs Pharma Ltd (BLISSGVS) closed at ₹704.7 on NSE on 25 September 2026, up 17.65 (2.57%) from the previous close.
Bliss Gvs Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol BLISSGVS.
Bliss Gvs Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 54.4.
Bliss Gvs Pharma Ltd has a dividend yield of 0.23%.
Bliss Gvs Pharma Ltd's 52-week high is ₹734.0 and its 52-week low is ₹118.0.
Bliss Gvs Pharma Ltd has a market capitalisation of ₹7,486 crore.
Bliss Gvs Pharma Ltd has a TopFund Quality Score of 64/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Bliss Gvs Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.